Pregabalin Capsule
Product Images NDC 60760-753

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-753 (Pregabalin 60760 753 60)

Label for Pregabalin 100 mg capsules from St. Mary's Medical Park Pharmacy. The label includes the proprietary and generic name, dosage form (capsules), strength (100 mg), package quantity (60 capsules), and NDC 60760-753-60. It provides directions to use as directed and storage instructions at 20°-25°C (68°-77°F). Manufacturing details indicate MSM Laboratories Private Limited, Telangana, India.*

FDA Label Image

Equation (Pregabain Gault Equation)

A text panel displaying a formula for estimating creatinine clearance (CLCr) in patients. The formula includes variables for age, weight, serum creatinine, and a multiplication factor for female patients. It is a pharmacokinetic calculation related to drug dosing considerations.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting percent of patients improved (y-axis) versus percent improvement in pain from baseline (x-axis) comparing Pregabalin at 200 mg, 100 mg, 25 mg three times a day, and placebo. The graph shows four separate curves representing each treatment group.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg taken three times a day (dashed line) with a placebo (dotted line), illustrating a higher percent of patients improved across various levels of pain improvement for the Pregabalin group.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The graph illustrates patient improvement rates at various levels of pain reduction.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A line graph comparing the percent improvement in pain from baseline versus the percent of patients improved for Pregabalin at doses of 100 mg and 200 mg administered three times a day, and placebo. The graph shows three curves representing each group, with the x-axis labeled as percent improvement in pain and the y-axis as percent of patients improved.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The graph illustrates patient improvement trends across varying pain improvement percentages.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar graph comparing responder rates (%) between placebo and various dosages of Pregabalin in two clinical studies labeled Study E1 and Study E3. The graph displays responder rates for placebo and Pregabalin dosages ranging from 50 mg/day to 600 mg/day with different dosing frequencies (BID, TID) along the x-axis and responder rate percentages on the y-axis. Study E1 shows increasing responder rates with higher Pregabalin doses. Study E3 compares placebo to 600 mg/day Pregabalin given BID and TID.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph depicting seizure reduction as median percentage change from baseline against dose in mg/day. Four treatment groups are shown with different symbols: Stukly E1BID (circle), Stukly E2BID (square), Stukly E3BID (triangle), and Stukly E3TID (open triangle). The graph includes significant p-values noting statistical differences at various dose levels, ranging from 0 to 600 mg/day.*

FDA Label Image

Pregabalin-figure-08 (Pregabalin Figure 08)

A vertical bar chart showing responder rates in three groups: Placebo (22.6%), 2.5 mg/kg/day dose (29.1%), and 10 mg/kg/day dose (40.6%). The chart includes the sample sizes for each group (Placebo: 93, 2.5 mg/kg/day: 103, 10 mg/kg/day: 96). The y-axis is labeled 'Responder Rate (%).'*

FDA Label Image

Pregabalin-figure-09 (Pregabalin Figure 09)

A line graph with multiple lines representing data trends over a range indicated on the horizontal axis. The vertical axis shows values from 0 to 100. The graph includes a legend with four different line styles, but no labels or specific data points are readable. Two vertical lines mark specific positions on the horizontal axis.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR over 180 days, comparing Pregabalin (solid line) and placebo (dashed line). The y-axis represents the percentage from 0% to 100%, and the x-axis shows days from 0 to 180. Pregabalin shows higher estimated survival without LTR compared to placebo throughout the study period.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved against percent improvement from baseline to Week 12 BOCF for Pregabalin and a placebo. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved. The graph includes two lines: a solid line for Pregabalin and a dotted line for placebo, showing higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved over baseline to Week 16 using BOCF analysis, showing two lines: Pregabalin (solid line) and Placebo (dashed line). The X-axis represents percent improvement from greater than 0 to 100, and the Y-axis represents percent of subjects improved, ranging from 0 to 100.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of Pregabalin shown as a skeletal formula illustrating its key functional groups including an amino group, carboxyl group, and an isobutyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.